PRPF38B

Across TCGA pan-cancer cohorts, PRPF38B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRPF38B data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPF38B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPF38B expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, LSCC, and GBM are the cancer types where PRPF38B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.625	0.933	.001	36	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.579	.004	19	view →
GBM	OS	Median	All	0.498	0.289	.008	6	view →
LUAD	DFS	Median	All	0.543	0.893	.014	6	view →
CCRCC	OS	Median	III,IV	0.651	0.922	.035	4	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRPF38B–HNSC (DFS)

Open the HNSC breakdown →